Arecor Therapeutics PLC - Asset Resilience Ratio

Latest as of December 2025: 38.62%

Arecor Therapeutics PLC (AREC) has an Asset Resilience Ratio of 38.62% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

GBX3.13 Million

≈ $380.71 USD Cash + Short-term Investments

Total Assets

GBX8.10 Million

≈ $985.66 USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2025)

This chart shows how Arecor Therapeutics PLC's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Arecor Therapeutics PLC to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Arecor Therapeutics PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Arecor Therapeutics PLC stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX3.13 Million	38.62%
Total Liquid Assets	GBX3.13 Million	38.62%

Asset Resilience Insights

Very High Liquidity: Arecor Therapeutics PLC maintains exceptional liquid asset reserves at 38.62% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Arecor Therapeutics PLC Industry Peers by Asset Resilience Ratio

Compare Arecor Therapeutics PLC's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	39.07%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%

Annual Asset Resilience Ratio for Arecor Therapeutics PLC (2022–2025)

The table below shows the annual Asset Resilience Ratio data for Arecor Therapeutics PLC.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	38.62%	GBX3.13 Million ≈ $380.71	GBX8.10 Million ≈ $985.66	+38.42pp
2024-12-31	0.21%	GBX18.00K ≈ $2.19	GBX8.72 Million ≈ $1.06K	-10.58pp
2023-12-31	10.79%	GBX1.66 Million ≈ $201.85	GBX15.38 Million ≈ $1.87K	-26.16pp
2022-12-31	36.94%	GBX8.04 Million ≈ $978.36	GBX21.77 Million ≈ $2.65K	--

pp = percentage points

About Arecor Therapeutics PLC

LSE:AREC UK Biotechnology

Market Cap

$275.63K

GBX2.27 Billion GBX

Market Cap Rank

#31116 Global

#992 in UK

Share Price

GBX60.00

Change (1 day)

-1.64%

52-Week Range

GBX59.00 - GBX92.50

All Time High

GBX450.00